Supplemental Information and Guidance for Vaccination Providers Regarding Use of 9-Valent HPV

Details

• Journal Article:
  Morbidity and Mortality Weekly Report (MMWR)
• Personal Author:
  Petrosky, Emiko ; Bocchini, Joseph A. ; Hariri, Susan ; Chesson, Harrell ; Curtis, C. Robinette ; Saraiya, Mona ; Unger, Elizabeth R. ; Markowitz, Lauri E.
• Corporate Authors:
  United States. Advisory Committee on Immunization Practices.
• Description:
  A 9-valent human papillomavirus (HPV) vaccine (9vHPV, Gardasil 9, Merck & Co.) was licensed for use in females and males in December 2014. The 9vHPV was the third HPV vaccine licensed in the United States by the Food and Drug Administration (FDA); the other vaccines are bivalent HPV vaccine (2vHPV, Cervarix, GlaxoSmithKline), licensed for use in females, and quadrivalent HPV vaccine (4vHPV, Gardasil, Merck & Co.), licensed for use in females and males.5 In February 2015, the Advisory Committee on Immunization Practices (ACIP) recommended 9vHPV as one of three HPV vaccines that can be used for routine vaccination of females and one of two HPV vaccines for routine vaccination of males.6 After the end of 2016, only 9vHPV will be distributed in the United States. In October 2016, ACIP updated HPV vaccination recommendations regarding dosing schedules.7 CDC now recommends two doses of HPV vaccine (0, 6–12 month schedule) for persons starting the vaccination series before the 15th birthday. Three doses of HPV vaccine (0, 1–2, 6 month schedule) continue to be recommended for persons starting the vaccination series on or after the 15th birthday and for persons with certain immunocompromising conditions. Guidance is needed for persons who started the series with 2vHPV or 4vHPV and may be completing the series with 9vHPV. The information below summarizes some of the recommendations included in ACIP Policy Notes and provides additional guidance.
• Subjects:
  Adolescent Adult Advisory Committees Child Female Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 Humans Immunization Schedule Male Papillomavirus Infections Papillomavirus Vaccines Practice Guidelines As Topic Young Adult

  More +
• Source:
  MMWR Morbidity Mortal Weekly Rep. 2015; 64(11):300-304.
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Pubmed ID:
  25811679
• Pubmed Central ID:
  PMC4584883
• Document Type:
  Journal Article
• Place as Subject:
  United States
• Location:
  North America
• Pages in Document:
  5 pdf pages
• Volume:
  64
• Issue:
  11
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR) Advisory Committee on Immunization Practices (ACIP)
• Main Document Checksum:
  urn:sha-512:3a8590606b890f69845721a2b65432f6d4283a5e713ad4021944ba9e90e8573b2ecb9189320356fff6c69be5fa39090b88aa297b28afcbee1ff5fc220cc2503a
• Download URL:
  https://stacks.cdc.gov/view/cdc/250722/cdc_250722_DS1.pdf
• File Type:
  [PDF - 78.69 KB ]